Biotech Drug Report Generated Jul 7, 2026

Qelbree

SUPN·SUPERNUS PHARMACEUTICALS, INC.

MIXED

Drug Impact Rating4/10

Trial Phase: Approved
Time to Market: Already approved and marketed since April 2021 (pediatric) and 2023 (adult)
Why 4/10: Qelbree is already fully FDA-approved for both pediatric and adult ADHD with no pending PDUFA or binary regulatory catalyst. The next hard catalysts are quarterly earnings reports and Paragraph IV litigation developments (generic challenge received May 2025), neither of which qualifies as a single make-or-break binary event. ImpactScore is 4 because the drug is central to Supernus (~37% of total revenue) but the defining binary has already passed.

Actionable Insight MIXED

Qelbree is a well-established commercial asset with steady 20%+ sales growth. The investor focus should be on (1) quarterly prescription trends as a lead indicator for revenue, (2) progress in the Paragraph IV patent litigation against generic filers, and (3) whether Qelbree's growth can offset declining legacy products. The stock already trades at ~$47 with analyst mean PT of ~$63 (~29% upside), pricing in continued momentum.

Price Chart

Loading chart...

Executive Summary

Qelbree (viloxazine/SPN-812) is Supernus Pharmaceuticals' lead growth product — a once-daily non-stimulant ADHD medication that was the first new non-stimulant ADHD drug approved in a decade. Launched in 2021 for children and expanded to adults in 2023, Qelbree has delivered strong commercial momentum: net sales hit $241M in 2024 (+72% YoY), exceeded $300M in 2025 (+26%), and reached $77.9M in Q1 2026 (+20% YoY). It competes mainly against Strattera (generic atomoxetine) in the non-stimulant segment and against a large field of stimulants. The key risk is a Paragraph IV patent challenge filed in May 2025 by generic manufacturers targeting Qelbree's six Orange Book patents (expiring 2029-2035). Supernus has diversified somewhat with three other growth products (GOCOVRI, ZURZUVAE, ONAPGO) but Qelbree remains the largest single revenue driver at roughly 37% of total company revenue.

How It Works

Qelbree is a non-stimulant ADHD medication that works by increasing levels of norepinephrine (a brain chemical that helps with focus and impulse control) and also modulating serotonin activity. Unlike stimulant ADHD drugs like Adderall or Vyvanse, it is not a controlled substance and has no known abuse potential. It's taken as a once-daily extended-release capsule.

Trial Status

Qelbree is fully FDA-approved and commercially available in the US for ADHD in pediatric patients (ages 6-17, approved April 2021) and adults (18+, approved 2023). A long-term Phase 3 open-label safety extension study (NCT02736656) is active but not recruiting, estimated to complete September 2026.

The Two-Sided Case

▲ Bull Case6

Qelbree is the first new non-stimulant ADHD drug approved in a decade, giving it a differentiated positioning vs both the generic Strattera and controlled-stimulant competitors (source: fiercpharma.com)

Strong commercial trajectory: Qelbree net sales grew 72% YoY to $241M in 2024, then 26% to over $300M in 2025, with Q1 2026 delivering another 20% increase to $77.9M (source: ir.supernus.com, sec.gov)

Prescription growth remains robust — Q1 2026 IQVIA prescriptions rose 19% YoY to ~255K — indicating continued share gains in the ADHD market (source: ir.supernus.com)

Supernus has diversified into a multi-product CNS company (4 growth products) reducing single-asset risk, and the stock has strong analyst support: 10 buy-equivalent ratings vs 2 hold, 0 sell, with a mean price target of ~$62.83 implying ~29% upside

Patent protection extends to 2029-2035 — recent Paragraph IV challenge is being vigorously defended, and Supernus has a history of defending IP (source: sec.gov, drugpatentwatch.com)

Qelbree is a non-controlled substance (no abuse potential, no DEA scheduling), a key advantage for formulary access and prescriber comfort vs stimulants (source: drugs.com)

▼ Bear Case5

Paragraph IV ANDA filings received May 2025 from multiple generic manufacturers pose a material patent-expiry overhang; if generic competition launches before patent expiry (2035), Qelbree's revenue could be severely eroded (source: sec.gov, stocktitan.net)

Qelbree's growth is already decelerating: from 72% revenue growth in 2024 to 26% in 2025 to 20% in Q1 2026 — as the product matures and faces increasing competition, this trend could continue (source: ir.supernus.com)

The ADHD market is highly competitive and dominated by cheap generics: Strattera (atomoxetine) is available as a generic non-stimulant, and generic Adderall XR is expected to further pressure pricing across the stimulant segment (source: ainvest.com)

Qelbree's revenue ($77.9M in Q1 2026) still represents a significant portion of Supernus's total revenue (~37%), so any setback would materially impact the company. Legacy products are declining, adding to reliance on Qelbree's continued growth (source: panabee.com)

The stock's ~29% implied upside to analyst PT already prices in continued strong execution; any miss on quarterly prescription trends or negative patent-litigation developments could lead to downside

Upcoming Catalysts

Q2 2026 earnings report (~early August 2026) — key check on Qelbree prescription growth and revenue trajectory
Paragraph IV patent litigation developments — court rulings or settlements with generic filers could materially impact the stock
Long-term safety study completion (NCT02736656) expected Sept 2026 — could support label enhancements
Potential label updates or expanded indications for Qelbree
ONAPGO second supplier FDA submission expected Q3 2026 (related company catalyst)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

SUPERNUS PHARMACEUTICALS, INC. COURT-RULING SUPN ·Originating report

Sources · 14

Hover a chip for the title

1 ir.supernus.com2 ir.supernus.com3 ir.supernus.com4 biospace.com5 sec.gov6 drugpatentwatch.com7 stocktitan.net8 fiercepharma.com9 fiercepharma.com10 sec.gov11 panabee.com12 en.wikipedia.org13 msn.com14 ainvest.com